EP0467908A1 - 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidine-1-yl)-pyrimidine hydroxyminoxidile presentant une activite antifibroblastique - Google Patents

6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidine-1-yl)-pyrimidine hydroxyminoxidile presentant une activite antifibroblastique

Info

Publication number
EP0467908A1
EP0467908A1 EP90905475A EP90905475A EP0467908A1 EP 0467908 A1 EP0467908 A1 EP 0467908A1 EP 90905475 A EP90905475 A EP 90905475A EP 90905475 A EP90905475 A EP 90905475A EP 0467908 A1 EP0467908 A1 EP 0467908A1
Authority
EP
European Patent Office
Prior art keywords
amino
activity
dihydro
hydroxy
hydroxypiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90905475A
Other languages
German (de)
English (en)
Inventor
Francesco Gatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEMIOS Srl BIO MEDICAL RESEARCH
Original Assignee
KEMIOS Srl BIO MEDICAL RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEMIOS Srl BIO MEDICAL RESEARCH filed Critical KEMIOS Srl BIO MEDICAL RESEARCH
Publication of EP0467908A1 publication Critical patent/EP0467908A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Definitions

  • the present invention refers to the use of 6-a ino-l ,2-dihydro-hydroxy-2-imino-( -hydroxypiperidin-l -yDpyridine for the preparation of a medicament having antifibrotic activity useful for the treatment of proliferation conditions of the connective tissue and collagen accumulation.
  • Is is known that pathological conditions such as keloids, hypertrophic scars and fibrotic conditions such as scleroderma, are characterized by an excessive proliferation of the connective tissue, whose main component is the finrous protein known as collagen. Said abnormal growth of the connective tissue, taking place also as a consequence of phlogistic processes of various kind (fractures, contusions, distortions, traumas etc.) hinders the physiological processes of tissue repair and healing.
  • minoxidil has been studied because of its additional capacity of stimulating hair growth.
  • the main pharmacological activity of minoxidil namely the antihypertensive and vasodilating activity, may limit the topical use of the drug, both in the known and widespread treatment of alopecias and in the proposed treatment of fibrotic conditions.
  • minoxidil metabolite according to the present invention for the preparation of a medicament having antifibrotic activity is therefore more advantageous in comparison with minoxidil because of possible side-effects that the latter may induce as a consequence • of its vasodilating and antihypertensive activity.
  • SKM/101 The new pharmacological activity of the minoxidil metabolite of the invention, hereinafter referred to as SKM/101, was confirmed by inhibition tests of the enzymes prolylhydroxylase and lysylhydroxylase in human skin fibroplasts cultures, according to the method reported in Dermatologica 175(2), 12-18, 1987. A further confirmation was obtained from in vivo tests using guinea-pigs on whose back a silastic valve was implanted, SKM/101 may be formulated in topical phar ⁇ maceutical compositions, using conventional techniques and excipients. Examples of suited pharmaceutical compo- sitions are lotions, creams, ointments, sprays, gauzes, plasters, balsams and the like.
  • a particularly convenient administration form consists of lyophilized bovine native collagen, impregnated with SKM/101 or its acceptable salts.
  • the concentration of the active principle or of its salts in the above cited pharmaceutical compositions may range from 0.2 to 20% by weight.
  • the compositions may also contain other active principles having complementary or anyhow useful activity such as vitamin A or its derivatives, vitamin E or its derivatives, ascorbic acid, glutathion, antioxidants.
  • the pharmaceutical compositions of the invention may be administered one or more times a day, according to the pathology to be treated and of the kind of used formulations.
  • plasters containing SKM/101 able to release slowly and gradually the active principle are particularly useful.
  • SKM/101 may also be administered by local infiltration using known methods, in place of cortison. The following examples further illustrate the invention.
  • Vitamine A acetate g 0.20
  • Vitamine E acetate g 0.20
  • Vitamine C acetate g 0.2
  • Each gauze 10 x 10 cm is soaked at saturation with 40 g of a mixture having the following composition: SKM/101 g 2.0 Collagen g 15.0 Glycerine g 10.0
  • Vitamine E acetate g 0.2 Purified water q.s, to g 40

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La 6-amino-1,2-dihydro-1-hydroxy-2-imino-4(4-hydroxypipéridine-1-yl)pyrimidine est dotée d'une activité antifibroplastique, et peut être utilisée pour la préparation d'un médicament utile pour le traitement d'états pathologiques caractérisés par la prolifération du tissu conjonctif.
EP90905475A 1989-04-13 1990-04-06 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidine-1-yl)-pyrimidine hydroxyminoxidile presentant une activite antifibroblastique Withdrawn EP0467908A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2012689 1989-04-13
IT8920126A IT1230056B (it) 1989-04-13 1989-04-13 Derivato di 4-(piperidin-1-il) piridina ad attivita' antifibroplastica.

Publications (1)

Publication Number Publication Date
EP0467908A1 true EP0467908A1 (fr) 1992-01-29

Family

ID=11164017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90905475A Withdrawn EP0467908A1 (fr) 1989-04-13 1990-04-06 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidine-1-yl)-pyrimidine hydroxyminoxidile presentant une activite antifibroblastique

Country Status (3)

Country Link
EP (1) EP0467908A1 (fr)
IT (1) IT1230056B (fr)
WO (1) WO1990011762A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3670765D1 (en) * 1985-01-25 1990-06-07 Upjohn Co Pyrimidinsulfate fuer haarwuchs.
FR2590897B1 (fr) * 1985-12-06 1988-02-19 Kemyos Bio Medical Research Sr Nouveaux derives de 6 amino 1,2-dihydro-1-hydroxy-2-imino-pyrimidine, leur procede de preparation et compositions cosmetiques les renfermant
GB8606368D0 (en) * 1986-03-14 1986-04-23 Unilever Plc Skin treatment composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9011762A1 *

Also Published As

Publication number Publication date
WO1990011762A1 (fr) 1990-10-18
IT1230056B (it) 1991-09-27
IT8920126A0 (it) 1989-04-13

Similar Documents

Publication Publication Date Title
US4826830A (en) Topical application of glyciphosphoramide
US4141977A (en) Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds
CN100420439C (zh) 双胍衍生物在制备具有瘢痕形成作用的医药产品中的应用
JP3487633B2 (ja) 皮膚疾患治療乳剤
SK285869B6 (sk) Zlúčeniny na liečbu kožných ochorení, ich použitie a farmaceutické prípravky s ich obsahom
US5846552A (en) Use of 2,4-diaminopyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders
JPWO1995030412A1 (ja) サイトカイン活性増強剤およびサイトカインの働きが低下した疾病の治療剤
WO1995030412A1 (fr) Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite
US6313179B1 (en) Treatment of hyperproliferative skin disorders with C18 to C20 aliphatic alcohols
JPH07557B2 (ja) 皮膚炎に対する治療用組成物
EP0467908A1 (fr) 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidine-1-yl)-pyrimidine hydroxyminoxidile presentant une activite antifibroblastique
KR20070097291A (ko) 프로피오니박테리움 아크네스에 대한 항균제
CA2087145C (fr) Composition pharmaceutique permettant d'accelerer la cicatrisation
EP0468969A1 (fr) Anti-angiogenique topique a usage d'inhibiteur de croissance capillaire
KR20160119690A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
JP2860550B2 (ja) 急性皮膚炎症治療剤
US20030125307A1 (en) Remedies for external use for allergic skin diseases
JP2003246737A (ja) 皮膚外用組成物
EP1394161B1 (fr) Adduit diester d'acide l-ascorbique-acide-2-0-maleique-alpha tocopherol 1-propanol et procede de production de ce dernier
JP3193028B2 (ja) ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤
US5891881A (en) Aminoheterocycle-substituted glycerols
JPH03275624A (ja) 新規な皮膚潰瘍治療剤
JPS63107935A (ja) 皮膚潰瘍治療剤
JPH101443A (ja) 感染性皮膚疾患治療用外用剤
JP3401476B2 (ja) 化粧料

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19921127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930408